News | April 07, 2008

Stubborn High Blood Pressure May Need Special Care

April 8, 2008 - People who are taking three or more drugs and still have high blood pressure have a condition known as resistant hypertension that may require special treatment, the American Heart Association said on Monday.

The guidelines are intended to help doctors and patients identify and control resistant hypertension, which affects as many as 30 percent of people with high blood pressure.

"It may be the fastest-growing component of hypertension in general - those patients needing three or more medicines," David Calhoun, M.D., of the University of Alabama at Birmingham and chair of the association's guideline writing committee said in a telephone interview.

Given that older age and obesity are two of the strongest risk factors associated with this kind of hypertension, the condition will likely become increasingly common as the U.S. population ages and grows heavier, Dr. Calhoun said.

Under the new guidelines, published online in the journal Hypertension, resistant hypertension also includes people who must take four or more drugs before they can get their blood pressure under control.

High blood pressure affects about 73 million people in the United States and an estimated 1 billion people globally. Poorly controlled hypertension increases the risk of heart attacks, stroke, kidney failure and heart failure.

"These patients with resistant hypertension are probably at even increased risk because of their long-standing, poorly controlled hypertension," Dr. Calhoun said.

Dr. Calhoun said the guidelines are the first to specifically address the treatment of resistant hypertension, which he said may be brought on by underlying conditions that need to be managed.
"Obesity, a high-salt diet, and sleep apnea are common contributing causes," he said. Resistant hypertension may also result from an excess of a hormone produced in the adrenal gland known as aldosterone, which can promote fluid retention.

Kidney disease and diabetes are also important contributors, Dr. Calhoun said.

The new guidelines stress that treatment should be tailored to individual patients and their underlying conditions.

If blood pressure cannot be controlled after working with a general doctor for six months, Dr. Calhoun said people should referred to a specialist.

(Editing by Maggie Fox and Eric Walsh)

Source: REUTERS

For more information: www.cms.gov


Related Content

News | Stents Drug Eluting

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
News | Stents Drug Eluting

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
News | Stents Drug Eluting

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
Home
News | Stents Drug Eluting

July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...

Home July 12, 2023
Home
News | Stents Drug Eluting

May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...

Home May 25, 2023
Home
News | Stents Drug Eluting

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...

Home January 02, 2023
Home
News | Stents Drug Eluting

December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...

Home December 23, 2022
Home
News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Subscribe Now